Cells

FROM INTELLIA

March 14, 2017

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

READ MORE

March 8, 2017

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

READ MORE

March 1, 2017

Intellia Therapeutics to Present at March Investor Healthcare Conferences

READ MORE

February 16, 2017

Intellia Therapeutics Conference Call to Address CRISPR/Cas9 U.S. Patent Interference Proceedings

READ MORE

February 15, 2017

INTELLIA THERAPEUTICS TO HOLD CONFERENCE CALL TO ADDRESS PATENT INTERFERENCE PROCEEDINGS

READ MORE

February 15, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.

READ MORE

February 14, 2017

Joint Statement of Intellia Therapeutics & CRISPR Therapeutics: Position Regarding Human Germline Gene Editing

READ MORE

February 1, 2017

Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference

READ MORE

January 11, 2017

Intellia Therapeutics Joins Genomics England's Industry Consortum

READ MORE

December 16, 2016

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

READ MORE

December 13, 2016

Intellia Therapeutics Names Graeme Bell Chief Financial Officer

READ MORE

December 1, 2016

Intellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline

READ MORE

November 1, 2016

Intellia Therapeutics Reports Financial Results for Third Quarter 2016

READ MORE

October 31, 2016

Intellia Therapeutics to Present at November Investor Healthcare Conferences

READ MORE

October 14, 2016

Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress

READ MORE

October 5, 2016

Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

READ MORE

September 1, 2016

Intellia Therapeutics to Present at September Investor Healthcare Conferences

READ MORE

August 29, 2016

Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components

READ MORE

August 4, 2016

Intellia Therapeutics Reports Financial Results for Second Quarter 2016

READ MORE

June 17, 2016

Intellia Therapeutics to Present at the Jefferies 2016 Healthcare Conference and the International BIO Convention

READ MORE

May 11, 2016

Intellia Therapeutics Announces Closing of Initial Public Offering

READ MORE

May 5, 2016

Intellia Therapeutics Announces Pricing of Initial Public Offering

READ MORE

April 22, 2016

Intellia Therapeutics Appoints Perry Karsen As Chairman Of Its Board Of Directors Read More

READ MORE

April 11, 2016

Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

READ MORE

March 9, 2016

Intellia Founders Awarded Distinguished Alpert Prize

READ MORE

January 12, 2016

Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9

READ MORE

December 14, 2015

Intellia Therapeutics Appoints Caroline Dorsa To Company's Board Of Directors

READ MORE

September 30, 2015

FierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015

READ MORE

September 1, 2015

Intellia Therapeutics Secures $70 Million in Series B Financing

READ MORE

August 6, 2015

Intellia Statement on Germline Editing

READ MORE

April 22, 2015

Intellia Therapeutics Announces Dr. Jennifer Doudna and Dr. Derrick Rossi to Join Company

READ MORE

April 22, 2015

Intellia Therapeutics Announces the Appointment of Dr. Sapna Srivastava as Chief Finance and Strategy Officer

READ MORE

January 7, 2015

Intellia Therapeutics, Novartis Form Collaboration to Develop New Cell Therapies Using CRISPR/Cas9 Technology

READ MORE

November 18, 2014

Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology

READ MORE

RECENT NEWS

February 13, 2017

A Year of Brutal Training for Racing in the Andes

READ MORE

February 9, 2017

Biotech Execs Blast Trump's Travel Ban

READ MORE

October 27, 2016

Space is at a premium for Cambridge startup Intellia

READ MORE

October 24, 2016

LISTEN: Gene-editing might eradicate disease — or be Pandora’s box in a bottle

READ MORE

August 3, 2016

Intellia’s CEO Nessan Bermingham, PhD, on Bloomberg Radio with Doni Bloomfield

READ MORE

July 29, 2016

Nessan Bermingham, Intellia CEO and President, Talks with CNBC About CRISPR Technology

READ MORE

May 11, 2016

The 2016 Dr. H.P. Heineken Prize for Biochemistry and Biophysics Awarded to Jennifer Doudna

READ MORE

May 5, 2016

Doudna named foreign member of UK’s Royal Society

READ MORE

March 14, 2016

Paul Ehrlich and Ludwig Darmstaedter Prize for J.A. Doudna and E. Charpentier

READ MORE

March 9, 2016

Alpert Prize Recognizes CRISPR Pioneers

READ MORE

February 15, 2016

Jennifer Doudna Answers Questions on CRISPR, Gene Editing's Future

READ MORE

December 18, 2015

And Science’s Breakthrough of the Year is …

READ MORE

December 14, 2015

Intellia Therapeutics Appoints Caroline Dorsa to Company’s Board of Directors

READ MORE

December 3, 2015

On Human Gene Editing: International Summit Statement

READ MORE

November 9, 2015

The Crispr Quandary

READ MORE

September 1, 2015

Intellia Closes on $70 Million Series B Round, Plans to Hire 20

READ MORE

September 1, 2015

Intellia Raises $70 Million for Gene-Editing Treatments

READ MORE

September 1, 2015

Xconomy – CRISPR Cash: Intellia The Latest Gene-Editing Firm to Nab Big

READ MORE

August 22, 2015

The Age of the Red Pen

READ MORE

July 7, 2015

The Researchers Behind 'The Biggest Biotech Discovery of the Century' Found it by Accident

READ MORE

June 18, 2015

Editing the Software of Life, for Fame and Fortune

READ MORE

May 30, 2015

Europa, Genes, and Wheels | FULL EPISODE | #268

READ MORE

April 16, 2015

Emmanuelle Charpentier & Jennifer Doudna

READ MORE

April 3, 2015

Who Owns CRISPR?

READ MORE

April 1, 2015

Mini Enzyme Moves Gene Editing Closer to the Clinic

READ MORE

March 19, 2015

Scientists Seek Ban on Method of Editing the Human Genome

READ MORE

March 6, 2015

Nature Biotech Honors Some Of 2014’s Best Academic Startups

READ MORE

January 7, 2015

CART + CRISPR = 1st-Of-Its-Kind Biotech Deal From Novartis, Intellia

READ MORE

November 18, 2014

Novartis Joins Atlas in Launching a CRISPR Cas Biotech With a $15M Bankroll

READ MORE

MEDIA CONTACT

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 (224)-804-4462
jenn.smoter@intelliatx.com

Click here for Investor Relations contact information